

## THC Form 7

### MONTHLY PROGRESS REPORT

April 2020

Name of CSE Issuer **THC BioMed Intl Ltd.**  
Trading Symbol: **THC**  
Number of Outstanding Listed Securities **158,463,056 common shares and 56,678,634 reserved for Issuance**  
Date: **May 5, 2020**

#### Report on Business

1. Provide a general overview and discussion of the development of the Issuer's business and operations over the previous month. Where the Issuer was inactive disclose this fact.

**On April 7, 2020, the Issuer announced that its new cannabis beverage, THC Kiss, would be available for sale to Medical Patients that week. The Issuer expects to begin its rollout of THC Kiss to the recreational market over the next few weeks.**

**THC Kiss is sold at compassionate pricing for registered medical patients at \$4.20 per 30ml beverage containing 10 mg of THC.**

**On April 8, 2020, the Issuer released its unaudited financial statements and Management's Discussion and Analysis for the six months ended January 31, 2020.**

**On April 20, 2020 the Issuer announced that it had reduced the price of its premium indoor-grown cannabis to \$4.20 per gram for registered medical patients.**

**The Issuer also reported that it had begun the sale and shipment of its THC Kiss cannabis beverage to registered medical patients.**

**The Issuer purchased a total of 137,000 Common Shares during the month of March for a total cost of \$14,385 as part of its NCIB. The consideration paid was determined by the market price and in accordance with the regulations applicable to the NCIBs. The shares are to be returned to the Issuer's treasury for cancellation.**

2. Provide a general overview and discussion of the activities of management.

**Management continues to work on the conduct of the company's business plan, growth and harvest of product, new product testing and expansion plans.**

3. Describe and provide details of any new products or services developed or offered. For resource companies, provide details of new drilling, exploration or production programs

and acquisitions of any new properties and attach any mineral or oil and gas or other reports required under Ontario securities law.

**On April 7, 2020 the Issuer announced that its new cannabis beverage, THC Kiss, would be available for sale to Medical Patients that week. The Issuer expects to begin its rollout of THC Kiss to the recreational market over the next few weeks.**

**THC KISS is a brand new cannabis beverage that is unlike those currently available in either the grey or legal cannabis markets. THC Kiss was developed by the Issuer using proprietary extraction methods invented by THC.**

**THC Kiss is sold at compassionate pricing for registered medical patients at \$4.20 per 30ml beverage containing 10 mg of THC.**

4. Describe and provide details of any products or services that were discontinued. For resource companies, provide details of any drilling, exploration or production programs that have been amended or abandoned.

**None.**

5. Describe any new business relationships entered into between the Issuer, the Issuer's affiliates or third parties including contracts to supply products or services, joint venture agreements and licensing agreements etc. State whether the relationship is with a Related Person of the Issuer and provide details of the relationship.

**None.**

6. Describe the expiry or termination of any contracts or agreements between the Issuer, the Issuer's affiliates or third parties or cancellation of any financing arrangements that have been previously announced.

**None.**

7. Describe any acquisitions by the Issuer or dispositions of the Issuer's assets that occurred during the preceding month. Provide details of the nature of the assets acquired or disposed of and provide details of the consideration paid or payable together with a schedule of payments if applicable, and of any valuation. State how the consideration was determined and whether the acquisition was from or the disposition was to a Related Person of the Issuer and provide details of the relationship.

**The Issuer purchased a total of 137,000 Common Shares during the month of March for a total cost of \$14,385 as part of its NCIB. The consideration paid was determined by the market price and in accordance with the regulations applicable to the NCIBs. The shares are to be returned to the Issuer's treasury for cancellation.**

8. Describe the acquisition of new customers or loss of customers.

**The Issuer has continued to register new patients.**

9. Describe any new developments or effects on intangible products such as brand names, circulation lists, copyrights, franchises, licenses, patents, software, subscription lists and trademarks.

**None.**

10. Report on any employee hiring's, terminations or lay-offs with details of anticipated length of lay-offs.

**None, except in the ordinary course of business.**

11. Report on any labour disputes and resolutions of those disputes if applicable.

**None.**

12. Describe and provide details of legal proceedings to which the Issuer became a party, including the name of the court or agency, the date instituted, the principal parties to the proceedings, the nature of the claim, the amount claimed, if any, if the proceedings are being contested, and the present status of the proceedings.

**None.**

13. Provide details of any indebtedness incurred or repaid by the Issuer together with the terms of such indebtedness.

**None.**

14. Provide details of any securities issued and options or warrants granted.

**None.**

15. Provide details of any loans to or by Related Persons.

**None.**

16. Provide details of any changes in directors, officers or committee members.

**None.**

17. Discuss any trends which are likely to impact the Issuer including trends in the Issuer's market(s) or political/regulatory trends.

**The Issuer's business involves certain risks and uncertainties that are inherent to the Issuer's industry. For disclosure on risks related to an investment in the Issuer, please refer to the Issuer's most recent Management's Discussion and Analysis**

under the titles “Financial Instruments and Risk Management” and “Other Risks and Uncertainties”, which is available on SEDAR at [www.sedar.com](http://www.sedar.com).

The outbreak of COVID-19 has significantly increased economic uncertainty. In addition, public and private sector policies and initiatives to reduce the transmission of COVID-19, such as the imposition of travel restrictions and the adoption of remote working, have impacted our business and operations. COVID-19 is impacting our contractors’ ability to provide services to us, including professional services such as accounting and auditing due to social distancing measures.

### Certificate of Compliance

The undersigned hereby certifies that:

1. The undersigned is a director and senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance.
2. As of the date hereof there were is no material information concerning the Issuer which has not been publicly disclosed.
3. The undersigned hereby certifies to CSE that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all CSE Requirements (as defined in CSE Policy 1).
4. All of the information in this Form 7 Monthly Progress Report is true.

Dated: **May 5, 2020**.

**John Miller**

\_\_\_\_\_  
Name of Director or Senior Officer

***"John Miller"***

\_\_\_\_\_  
Signature

**President and CEO**

\_\_\_\_\_  
Official Capacity

<b>Issuer Details</b>		
-----------------------	--	--

Name of Issuer: <b>THC BioMed Intl Ltd.</b>	For Month End <b>April</b>	Date of Report: YYYYMMDD <b>2020/05/05</b>
Issuer Address: <b>P.O. Box 20033 Towne Centre</b>		
City/Province/Postal Code: <b>Kelowna, BC V1Y 9H2</b>	Issuer Fax No.: <b>N/A</b>	Issuer Telephone No. <b>(250) 870-2512</b>
Contact Name: <b>John Miller</b>	Contact Position: <b>President &amp; CEO</b>	Contact Telephone No. <b>(250) 870-2512</b>
Contact Email Address: <b>info@thcbiomed.com</b>	Web Site Address: <b>www.thcbiomed.com</b>	